Core Insights - Norges Bank increased its stake in Kanglong Chemical (300759) by 518,200 shares at a price of HKD 25.7617 per share, totaling approximately HKD 13.3497 million [1] - Following this transaction, Norges Bank's total shareholding in Kanglong Chemical is approximately 14.7304 million shares, representing a holding percentage of 5.01% [1]

Core Viewpoint - Norges Bank increased its stake in Kanglong Chemical (03759) by purchasing 518,200 shares at a price of HKD 25.7617 per share, totaling approximately HKD 13.3497 million, bringing its total holdings to about 14.7304 million shares, which represents a 5.01% ownership stake [1] Summary by Category - **Share Purchase Details** - Norges Bank acquired 518,200 shares of Kanglong Chemical at HKD 25.7617 per share [1] - The total investment amounted to approximately HKD 13.3497 million [1] - **Post-Investment Holdings** - Following the purchase, Norges Bank's total shareholding in Kanglong Chemical reached approximately 14.7304 million shares [1] - The updated ownership percentage stands at 5.01% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | ...

Core Insights - The CXO (Contract Research Organization) sector in A-shares shows strong growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters [1] - In the third quarter alone, 21 companies achieved year-on-year revenue growth, driven by international demand for innovative drugs and a supportive policy environment [2] Industry Overview - The innovative drug industry is experiencing a dual boost from policy support and surging demand, which is activating new drug research and development needs, benefiting the CXO sector [2] - The National Healthcare Security Administration and the National Health Commission issued measures to support high-quality development of innovative drugs, proposing 16 policies to enhance the entire chain of support [2] Company Performance - Several CXO companies reported robust order backlogs for the first three quarters. For instance, WuXi AppTec reported a backlog of 59.88 billion yuan, a 41.2% increase year-on-year [2] - Innosilicon reported a nearly 20% increase in order amounts compared to the end of 2024, while Haoyuan reported a 50% year-on-year increase in its small molecule business orders [3] Market Trends - The first half of the year saw a surge in Chinese innovative drugs going global, with total foreign licensing transactions reaching $60 billion, accounting for 99% of global related transactions [3] - Morgan Stanley's healthcare research head in Greater China anticipates stable long-term growth in foreign licensing transactions for Chinese innovative drugs, with multinational companies likely to be more active in acquiring Chinese assets [3] Future Outlook - The CXO industry is expected to benefit from a combination of demand recovery and structural upgrades, with policies, capital, and technology contributing to a more certain industry development [3] - The industry is transitioning from "scale dividends" to "technology premiums," with technological iteration and process innovation becoming the core of competition [3]

Core Viewpoint - Kanglong Chemical (300759) announced that one of its actual controllers, Mr. Lou Xiaoqiang, has pledged part of his shares, while Ningbo Longtai Kang Investment Management Co., Ltd. has released part of its pledged shares [1] Summary by Relevant Sections - Share Pledge: Mr. Lou Xiaoqiang pledged 2.154 million shares of the company [1] - Share Release: Longtai Kang released 3.75 million shares from pledge [1]

智通财经APP讯，康龙化成(03759)发布公告，近日接到公司实际控制人之一楼小强先生及其一致行动人 宁波龙泰康投资管理有限公司(以下简称"龙泰康")的函告，获悉楼小强先生将其所持有的公司部分股份 进行了质押，龙泰康将其所持有的公司部分股份进行了解除质押。楼小强质押215.4万股公司股份,龙泰 康解除质押375万股公司股份。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「 聯交所 」）及香港中央結算有限公司 （「 香港結算 」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 中華人民共和國，北京 2025年11月3日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 证券代码：300759 证券简称：康龙化成 公告编号：2025-063 康龙化成（北京）新药技术股份有限 ...

Core Viewpoint - Goldman Sachs has slightly reduced its net profit forecasts for Kanglong Chemical (03759) for the years 2025 to 2027, while maintaining a "Buy" rating for its H-shares and a neutral rating for its A-shares [1] Group 1: Financial Performance - Kanglong Chemical's Q3 revenue reached 3.65 billion RMB, representing a year-on-year growth of 13.4% and a quarter-on-quarter growth of 9.1%, slightly exceeding Goldman Sachs' previous expectation of 3.48 billion RMB [1] - The adjusted non-IFRS net profit margin improved to 12.9%, compared to 11.3% in Q1 and 12.2% in Q2, benefiting from increased utilization and operational leverage [1] Group 2: Management Guidance - The management has raised its full-year revenue growth guidance from 10%-15% to 12%-16%, indicating a Q4 year-on-year growth of 6%-20% [2] - The management remains confident in achieving the revised guidance, citing strong growth in CMC orders, ongoing capacity expansion, and improved core business profit margins [2] Group 3: Strategic Outlook - Continued investment in the biopharmaceutical sector and strategic acquisitions are expected to strengthen Kanglong Chemical's growth and leadership position in the CDMO field [2]

Core Viewpoint - Goldman Sachs has slightly reduced its net profit forecasts for Kanglong Chemical (300759) for the years 2025 to 2027 by 0.1%, 0.1%, and 0.5% respectively, while maintaining a "Buy" rating for its H-shares and a neutral rating for its A-shares [1] Group 1: Financial Performance - Kanglong Chemical reported third-quarter revenue of 3.65 billion RMB, representing a year-on-year growth of 13.4% and a quarter-on-quarter increase of 9.1%, slightly above Goldman Sachs' previous expectation of 3.48 billion RMB [1] - The growth in revenue was primarily driven by sustained momentum in the CMC and bioscience sectors, with contributions from the top twenty pharmaceutical clients increasing [1] - The non-IFRS adjusted net profit margin improved to 12.9%, compared to 11.3% in the first quarter and 12.2% in the second quarter, benefiting from increased utilization and operational leverage [1] Group 2: Management Guidance - The management of Kanglong Chemical has raised its full-year revenue growth guidance from 10%-15% year-on-year to 12%-16%, indicating a fourth-quarter growth of 6%-20% [2] - It is expected that the profit margin in the fourth quarter will further improve compared to the first three quarters, although the overall non-IFRS profit margin for the year may be slightly lower than in 2024 due to profit margin dilution from new capacity released in the first quarter [2] - Management remains confident in achieving the revised guidance, citing strong growth in CMC orders, ongoing capacity expansion, and improvements in core business profit margins [2]

关于公司实际控制人及其一致行动人股份质押和解除质押 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人之一楼小强先生及其一致行动人宁波龙泰康投资管理有限公司（以 下简称"龙泰康"）的函告，获悉楼小强先生将其所持有的公司部分股份进行了 质押，龙泰康将其所持有的公司部分股份进行了解除质押，具体情况如下： | | 是否为控股 | | 占其所 | 占公 司总 | 是否 | 是否 为补 | 质押起 | 质押到 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股东或第一 | 本次质押 | 持股份 | | 为限 | | | | | 质权人 | 质押用 | | 名称 | 大股东及其 | 数量（股） | 比例 | 股本 | 售股 | 充质 | 始日 | 期日 | | | 途 | | | 一致行动人 | | | 比例 | | 押 ...